Galera to Present at the Jefferies Virtual Healthcare Conference
May 26 2021 - 7:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
present at the Jefferies Virtual Healthcare Conference on
Wednesday, June 2, 2021, at 4:00 p.m. ET.
A live webcast of the presentation will be accessible from the
Investors page of Galera’s website, investors.galeratx.com. An
archived version of the webcast will be available in the News &
Events section of the Investors page of Galera’s website for 30
days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on developing and commercializing a pipeline of
novel, proprietary therapeutic candidates that have the potential
to transform radiotherapy in cancer. Galera’s lead product
candidate is avasopasem manganese (GC4419, also referred to as
avasopasem), a selective small molecule dismutase mimetic initially
being developed for the reduction of radiation-induced severe oral
mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN
trial to assess its ability to reduce the incidence and severity of
SOM induced by radiotherapy in patients with locally advanced head
and neck cancer (HNC), its lead indication. It is also being
studied in the EUSOM Phase 2a multi-center trial in Europe
assessing the safety of avasopasem in patients with HNC undergoing
standard-of-care radiotherapy, the AESOP Phase 2a trial to assess
its ability to reduce the incidence of esophagitis induced by
radiotherapy in patients with lung cancer, and a Phase 2 trial in
hospitalized patients who are critically ill with COVID-19. A pilot
Phase 1/2 trial of GC4419 in combination with stereotactic body
radiation therapy (SBRT) in patients with locally advanced
pancreatic cancer (LAPC) has completed enrollment and reported
updated results, with follow-up ongoing. The FDA granted Fast Track
and Breakthrough Therapy designations to avasopasem for the
reduction of SOM induced by radiotherapy. Galera’s second dismutase
mimetic product candidate, GC4711, is being developed specifically
to augment the anti-cancer efficacy of SBRT, and is currently being
studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in
patients with non-small cell lung cancer and the GRECO-2 Phase 2b
trial in combination with SBRT in patients with LAPC. Galera is
headquartered in Malvern, PA. For more information, please
visit www.galeratx.com.
Investor Contacts:Christopher DegnanGalera
Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
William WindhamSolebury
Trout646-378-2946wwindham@soleburytrout.com
Media Contact:Zara LockshinSolebury
Trout330-417-6250zlockshin@soleburytrout.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024